F Imkamp1, Y Tolkach2, M Wolters3, S Jutzi4, M Kramer5, T Herrmann6. 1. Clinic for Urology and Urologic Oncology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. Imkamp.florian@mh-hannover.de. 2. Clinic for Urology and Urologic Oncology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. Tolkach.iurii@mh-hannover.de. 3. Clinic for Urology and Urologic Oncology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. wolters.mathias@mh-hannover.de. 4. Clinic for Urology and Urologic Oncology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. jutzi.stephan@mh-hannover.de. 5. Clinic for Urology and Urologic Oncology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. Kramer.mario@mh-hannover.de. 6. Clinic for Urology and Urologic Oncology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. herrmann.thomas@mh-hannover.de.
Abstract
PURPOSE: Nephron-sparing surgery (NSS) is the gold standard treatment for resectable renal tumors. In the last decade, laparoscopic partial nephrectomy (LPN) has evolved in technical, surgical and oncological aspects and is an accepted treatment option for local-stage renal tumors. Improvements in not only surgical techniques, but also potent hemostats have encouraged this evolution. Here, we report our initial experiences with a new hemostatic agent, Hemopatch(®) (polyethylene glycol-coated collagen patch, Baxter), in zero-ischemia LPN. METHODS: Seven patients with confirmed renal masses were enrolled and subjected to zero-ischemia LPN. In all cases, Hemopatch(®) was applied to the tumor resection site after suturing of the renal parenchyma. The following clinical data were captured for analysis: staging information, PADUA and RENAL nephrometry scores, operation time, blood loss, complications, pathology and hospitalization length. RESULTS: The median tumor size was 30.0 mm (range 9.5-72). The median PADUA and RENAL nephrometry scores were 6 (range 6-7) and 4 (range 4-6), respectively. All LPNs were performed with the zero-ischemia technique. In six of the seven patients, parenchymal suturing of the resection site was performed. No uncontrolled bleeding was observed. The median operation duration was 139 min (range 103-194), the median blood loss was 325 cc (range 50-700) and the median hospitalization length was 6 days (range 4-7). Hemopatch(®) provided sufficient hemostasis in all cases. No postoperative complications were observed. CONCLUSIONS: Although this study is limited to a small set of initial experiences with Hemopatch(®) in LPN, it proves the feasibility and reliability of this new hemostat. Following further evaluation in prospective randomized comparative studies, Hemopatch(®) might represent a promising tool in NSS.
PURPOSE: Nephron-sparing surgery (NSS) is the gold standard treatment for resectable renal tumors. In the last decade, laparoscopic partial nephrectomy (LPN) has evolved in technical, surgical and oncological aspects and is an accepted treatment option for local-stage renal tumors. Improvements in not only surgical techniques, but also potent hemostats have encouraged this evolution. Here, we report our initial experiences with a new hemostatic agent, Hemopatch(®) (polyethylene glycol-coated collagen patch, Baxter), in zero-ischemia LPN. METHODS: Seven patients with confirmed renal masses were enrolled and subjected to zero-ischemia LPN. In all cases, Hemopatch(®) was applied to the tumor resection site after suturing of the renal parenchyma. The following clinical data were captured for analysis: staging information, PADUA and RENAL nephrometry scores, operation time, blood loss, complications, pathology and hospitalization length. RESULTS: The median tumor size was 30.0 mm (range 9.5-72). The median PADUA and RENAL nephrometry scores were 6 (range 6-7) and 4 (range 4-6), respectively. All LPNs were performed with the zero-ischemia technique. In six of the seven patients, parenchymal suturing of the resection site was performed. No uncontrolled bleeding was observed. The median operation duration was 139 min (range 103-194), the median blood loss was 325 cc (range 50-700) and the median hospitalization length was 6 days (range 4-7). Hemopatch(®) provided sufficient hemostasis in all cases. No postoperative complications were observed. CONCLUSIONS: Although this study is limited to a small set of initial experiences with Hemopatch(®) in LPN, it proves the feasibility and reliability of this new hemostat. Following further evaluation in prospective randomized comparative studies, Hemopatch(®) might represent a promising tool in NSS.
Entities:
Keywords:
Hemopatch; Hemostasis; Laparoscopic; Partial nephrectomy; Renal cancer
Authors: V Arnoux; J L Descotes; G Fiard; N Terrier; B Boillot; C Thuillier; J J Rambeaud; J A Long Journal: Prog Urol Date: 2012-12-07 Impact factor: 0.915
Authors: Anudeep Mukkamala; Christopher L Allam; Jonathan S Ellison; Khaled S Hafez; David C Miller; Jeffrey S Montgomery; Alon Z Weizer; J Stuart Wolf Journal: Urology Date: 2014-04-06 Impact factor: 2.649
Authors: Inderbir S Gill; Mihir M Desai; Jihad H Kaouk; Anoop M Meraney; David P Murphy; Gyung Tak Sung; Andrew C Novick Journal: J Urol Date: 2002-02 Impact factor: 7.450
Authors: Alessandro Antonelli; Andrea Minervini; Andrea Mari; Riccardo Bertolo; Giampaolo Bianchi; Alberto Lapini; Nicola Longo; Giuseppe Martorana; Vincenzo Mirone; Giuseppe Morgia; Giacomo Novara; Francesco Porpiglia; Bernardo Rocco; Bruno Rovereto; Riccardo Schiavina; Claudio Simeone; Mario Sodano; Carlo Terrone; Vincenzo Ficarra; Marco Carini; Sergio Serni Journal: Int J Urol Date: 2014-08-19 Impact factor: 3.369
Authors: Andreas Becker; Lea Pradel; Luis Kluth; Marianne Schmid; Christian Eichelberg; Sascha Ahyai; Quoc Trinh; Daniel Seiler; Roland Dahlem; Jens Hansen; Michael Rink; Mario Zacharias; Anja Mehnert; Corinna Bergelt; Margit Fisch; Felix K H Chun Journal: World J Urol Date: 2014-05-31 Impact factor: 4.226
Authors: Marie C Hupe; Maximilian Büttner; Pouriya Faraj Tabrizi; Axel S Merseburger; Markus A Kuczyk; Florian Imkamp Journal: Adv Ther Date: 2020-12-04 Impact factor: 3.845
Authors: Carlo Lombardo; Santiago Lopez-Ben; Ugo Boggi; Piotr Gutowski; Tomas Hrbac; Lukas Krska; Javier Marquez-Rivas; Domenico Russello; Elisa York; Mario Zacharias Journal: Updates Surg Date: 2022-08-20